Sorry, you need to enable JavaScript to visit this website.

TORISEL® (temsirolimus) Overdosage


There is no specific treatment for TORISEL intravenous overdose. TORISEL has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of TORISEL greater than 25 mg.

What's New

No Current Announcements.


Please enter your search term(s) for TORISEL®